Literature DB >> 12011543

Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis.

K Roos1, C Brunswig-Pitschner, R Kostrica, M Pietola, B Leroy, M Rangaraju, Y Boutalbi.   

Abstract

BACKGROUND: The efficacy and tolerability of oral telithromycin 800 mg once daily for 5 vs. 10 days were assessed in patients with acute maxillary sinusitis (AMS).
METHODS: Adults (n = 341) with confirmed AMS diagnosed on clinical signs and symptoms and sinus X-ray showing total opacity or air-fluid level were randomized to receive oral telithromycin for 5 days (followed by placebo for 5 days; n = 170) or 10 days (n = 171). Causative pathogens were isolated by pretreatment sinus puncture (day 1). Clinical and bacteriologic outcomes, and safety and tolerability endpoints were assessed.
RESULTS: Clinical cure rates post-therapy (per-protocol; days 17-21) were comparable (91.1% in the 5-day group, n = 123; 91.0% in the 10-day group, n = 133). Bacteriologic eradication rates (per-protocol) were also similar (90.7 vs. 91.3%). Both regimens were well tolerated.
CONCLUSIONS: A 5-day course of telithromycin 800 mg once daily is an effective, well-tolerated treatment for adults with AMS, comparable to a 10-day regimen. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011543     DOI: 10.1159/000057670

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

1.  Telithromycin: a novel agent for the treatment of community-acquired upper respiratory infections.

Authors:  Mai P Tran
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

Review 2.  Sinusitis (acute).

Authors:  Kim Ah-See
Journal:  BMJ Clin Evid       Date:  2011-12-21

Review 3.  Ketolides in the treatment of community-acquired respiratory tract infections: A review.

Authors:  Martin S Lipsky
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

Review 4.  Short-course antimicrobial therapy of respiratory tract infections.

Authors:  David Guay
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Sinusitis (acute).

Authors:  Kim Ah-See
Journal:  BMJ Clin Evid       Date:  2008-03-10

Review 7.  Acute rhinosinusitis in adults: an update on current management.

Authors:  Ajmal Masood; Ioannis Moumoulidis; Jaan Panesar
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

8.  Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Alexandros P Grammatikos; Dimitrios K Matthaiou
Journal:  Br J Clin Pharmacol       Date:  2008-09-19       Impact factor: 4.335

9.  Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis.

Authors:  Horacio Ariza; Ramon Rojas; Peter Johnson; Richard Gower; Alice Benson; Janet Herrington; Renee Perroncel; Peter Pertel
Journal:  BMC Ear Nose Throat Disord       Date:  2006-04-28

10.  Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.

Authors:  George G Zhanel; Tamiko Hisanaga; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.